Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addiction.
Am J Addict
; 28(4): 311-317, 2019 07.
Article
en En
| MEDLINE
| ID: mdl-31087723
ABSTRACT
BACKGROUND AND OBJECTIVES:
Disulfiram has been beneficial in treating cocaine addiction in several studies. Patients with two SLC6A3 (DAT1) rs28363170 10-repeat alleles who have with genetically high dopamine transporter (DAT) levels may benefit from increased dopamine levels resulting from disulfiram treatment.METHODS:
After stabilization for 2 weeks on methadone, 70 cocaine and opioid codependent patients were randomized into disulfiram and placebo groups for 12 weeks of treatment. We genotyped the SLC6A3 (DAT1) 40 bp 3'-untranslated region variable number tandem repeat variant and evaluated its role in moderating disulfiram efficacy for cocaine dependence.RESULTS:
Among the 10,10-repeat genotype group, cocaine-positive urines dropped from 78% to 48% and from 80% to 75% among the 9-repeat carrier group in the disulfiram group (P = 0.0001, with an effect size of 0.09). No difference was observed in cocaine-positive urines in the placebo group between the 10,10-repeat genotype and the 9-allele carrier patients. CONCLUSIONS AND SCIENTIFICSIGNIFICANCE:
We found that patients with genetically higher DAT levels had better treatment outcomes with disulfiram pharmacotherapy of cocaine dependence than those with lower DAT levels. (Am J Addict 2019;28311-317).
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Polimorfismo Genético
/
Repeticiones de Minisatélite
/
Trastornos Relacionados con Cocaína
/
Disulfiram
/
Proteínas de Transporte de Dopamina a través de la Membrana Plasmática
/
Inhibidores del Acetaldehído Deshidrogenasa
Tipo de estudio:
Clinical_trials
Límite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Am J Addict
Asunto de la revista:
TRANSTORNOS RELACIONADOS COM SUBSTANCIAS
Año:
2019
Tipo del documento:
Article